Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer

Osimertinib and dacomitinib are approved as first-line treatment of EGFR-mutant NSCLC but resistance can arise. Here, the authors use a computational model to identify an optimal dosing schedule for osimertinib and dacomitinib combination therapy that was confirmed tolerable and effective in an ongo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kamrine E. Poels, Adam J. Schoenfeld, Alex Makhnin, Yosef Tobi, Yuli Wang, Heidie Frisco-Cabanos, Shaon Chakrabarti, Manli Shi, Chelsi Napoli, Thomas O. McDonald, Weiwei Tan, Aaron Hata, Scott L. Weinrich, Helena A. Yu, Franziska Michor
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/f560d9720b2540fab5539f7d8afa3e27
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f560d9720b2540fab5539f7d8afa3e27
record_format	dspace
spelling	oai:doaj.org-article:f560d9720b2540fab5539f7d8afa3e272021-12-02T17:39:48ZIdentification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer10.1038/s41467-021-23912-42041-1723https://doaj.org/article/f560d9720b2540fab5539f7d8afa3e272021-06-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-23912-4https://doaj.org/toc/2041-1723Osimertinib and dacomitinib are approved as first-line treatment of EGFR-mutant NSCLC but resistance can arise. Here, the authors use a computational model to identify an optimal dosing schedule for osimertinib and dacomitinib combination therapy that was confirmed tolerable and effective in an ongoing phase I clinical trial.Kamrine E. PoelsAdam J. SchoenfeldAlex MakhninYosef TobiYuli WangHeidie Frisco-CabanosShaon ChakrabartiManli ShiChelsi NapoliThomas O. McDonaldWeiwei TanAaron HataScott L. WeinrichHelena A. YuFranziska MichorNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Kamrine E. Poels Adam J. Schoenfeld Alex Makhnin Yosef Tobi Yuli Wang Heidie Frisco-Cabanos Shaon Chakrabarti Manli Shi Chelsi Napoli Thomas O. McDonald Weiwei Tan Aaron Hata Scott L. Weinrich Helena A. Yu Franziska Michor Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer
description	Osimertinib and dacomitinib are approved as first-line treatment of EGFR-mutant NSCLC but resistance can arise. Here, the authors use a computational model to identify an optimal dosing schedule for osimertinib and dacomitinib combination therapy that was confirmed tolerable and effective in an ongoing phase I clinical trial.
format	article
author	Kamrine E. Poels Adam J. Schoenfeld Alex Makhnin Yosef Tobi Yuli Wang Heidie Frisco-Cabanos Shaon Chakrabarti Manli Shi Chelsi Napoli Thomas O. McDonald Weiwei Tan Aaron Hata Scott L. Weinrich Helena A. Yu Franziska Michor
author_facet	Kamrine E. Poels Adam J. Schoenfeld Alex Makhnin Yosef Tobi Yuli Wang Heidie Frisco-Cabanos Shaon Chakrabarti Manli Shi Chelsi Napoli Thomas O. McDonald Weiwei Tan Aaron Hata Scott L. Weinrich Helena A. Yu Franziska Michor
author_sort	Kamrine E. Poels
title	Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer
title_short	Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer
title_full	Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer
title_fullStr	Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer
title_full_unstemmed	Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer
title_sort	identification of optimal dosing schedules of dacomitinib and osimertinib for a phase i/ii trial in advanced egfr-mutant non-small cell lung cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/f560d9720b2540fab5539f7d8afa3e27
work_keys_str_mv	AT kamrineepoels identificationofoptimaldosingschedulesofdacomitinibandosimertinibforaphaseiiitrialinadvancedegfrmutantnonsmallcelllungcancer AT adamjschoenfeld identificationofoptimaldosingschedulesofdacomitinibandosimertinibforaphaseiiitrialinadvancedegfrmutantnonsmallcelllungcancer AT alexmakhnin identificationofoptimaldosingschedulesofdacomitinibandosimertinibforaphaseiiitrialinadvancedegfrmutantnonsmallcelllungcancer AT yoseftobi identificationofoptimaldosingschedulesofdacomitinibandosimertinibforaphaseiiitrialinadvancedegfrmutantnonsmallcelllungcancer AT yuliwang identificationofoptimaldosingschedulesofdacomitinibandosimertinibforaphaseiiitrialinadvancedegfrmutantnonsmallcelllungcancer AT heidiefriscocabanos identificationofoptimaldosingschedulesofdacomitinibandosimertinibforaphaseiiitrialinadvancedegfrmutantnonsmallcelllungcancer AT shaonchakrabarti identificationofoptimaldosingschedulesofdacomitinibandosimertinibforaphaseiiitrialinadvancedegfrmutantnonsmallcelllungcancer AT manlishi identificationofoptimaldosingschedulesofdacomitinibandosimertinibforaphaseiiitrialinadvancedegfrmutantnonsmallcelllungcancer AT chelsinapoli identificationofoptimaldosingschedulesofdacomitinibandosimertinibforaphaseiiitrialinadvancedegfrmutantnonsmallcelllungcancer AT thomasomcdonald identificationofoptimaldosingschedulesofdacomitinibandosimertinibforaphaseiiitrialinadvancedegfrmutantnonsmallcelllungcancer AT weiweitan identificationofoptimaldosingschedulesofdacomitinibandosimertinibforaphaseiiitrialinadvancedegfrmutantnonsmallcelllungcancer AT aaronhata identificationofoptimaldosingschedulesofdacomitinibandosimertinibforaphaseiiitrialinadvancedegfrmutantnonsmallcelllungcancer AT scottlweinrich identificationofoptimaldosingschedulesofdacomitinibandosimertinibforaphaseiiitrialinadvancedegfrmutantnonsmallcelllungcancer AT helenaayu identificationofoptimaldosingschedulesofdacomitinibandosimertinibforaphaseiiitrialinadvancedegfrmutantnonsmallcelllungcancer AT franziskamichor identificationofoptimaldosingschedulesofdacomitinibandosimertinibforaphaseiiitrialinadvancedegfrmutantnonsmallcelllungcancer
_version_	1718379800640356352

Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer

Ejemplares similares